Rahul Chaturvedi, Founder & CEO, Clora
I founded Clora to organize the world’s life sciences talent. We’re applying technology to accelerate development by enabling companies to access specialized consultants time and cost-effectively. Prior to Clora, I was the head of clinical development at several biopharma companies. I’ve led development activities for 20+ Phase II/III programs that have resulted in 6 product approvals to date. Additionally, I’ve managed business development initiatives in Europe, Asia, and Latin America.

Joe Collura, Partner & CEO, Stealth Mode Biotech
Bio coming soon.

Cris De Luca, Partner, Sanofi Ventures
Cris joined Sanofi Ventures in 2020 to lead investments in digital health and data science innovation. He holds a 20-year track record of building startups, tech innovation platforms, and healthtech deal making with some of the largest organizations in the world. Prior to Sanofi, Cris was a founding member of Johnson & Johnson Innovation and Global Head of Digital Innovation since 2013. He held chief digital and data responsibilities, driving digital health strategy and new venture partnerships throughout J&J Innovation spanning the Pharmaceutical, Consumer and Medical Device businesses.

Previously, Cris led emerging technology programs within research informatics at Novartis for six years. With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra-Light Startups, one of the largest and oldest startup venture pitch accelerators in the U.S, catalyzing hundreds of companies in Boston, NYC, and Silicon Valley, leading to several acquisitions by major tech companies. Cris was named 40 Under 40 by the Boston Business Journal and a Top 40 Healthcare Transformer by MM&M Magazine.

Cris currently serves on the boards of Aetion, Click Tx, Empatica, Medisafe, Nucleai, and Omada. Cris holds a M.Sc. in Computer Information Systems from Boston University and a B.S. in Business Administration from Suffolk University.

Bill Fitzgerald, Head of Biotechnology Markets Americas, Google
Bio coming soon.

Luba Greenwood, Managing Partner, Binney Street Capital, Dana-Farber Cancer Institute
Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. Luba has served as the Chief Executive Officer and Chair of the Board of Kojin Therapeutics, a leader in ferroptosis. She currently serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has founded, investing and building companies across therapeutics, diagnostics, and digital sectors. She has also served as a lecturer at Harvard University in the School of Engineering and Applied Sciences.

Ms. Greenwood has extensive board experience globally and serves on public and private boards, across multiple industries, including healthcare and tech, and has successfully contributed to the growth and profitability of numerous organizations, bringing her operational, industry, and financing expertise. She has a proven track record of building world-class teams and companies, building SABs with renown scientists and industry leaders, driving digital transformation and artificial intelligence initiatives, guiding companies through mergers & acquisitions, complex business development transactions, financing, and organizational change and scaling. With a strong understanding of board dynamics and corporate governance best practices, and as a former lawyer, she has also guided organizations through compliance, activist actions, and human resources challenges. She has served as Chair of the board as well as on the Compensation, Audit, and Nomination committees of a number of companies including In8Bio (INAB), BenchSci, Swiss-based Stalicla, Abcam (Abcam), where she has spearheaded the sale to Danaher (DHR), and non-profit, Massachusetts Biotechnology Council (MassBio). 

Ms. Greenwood has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also led diagnostics BD and established and led the East Coast Innovation Hub. Luba has led $5B+ in M&A, BD deals, and investments across multiple therapeutic areas, diagnostics, life sciences, and tech sectors globally. She has also co-founded and advised biotech and digital health companies in the immunotherapy, AI/ML, women's health, and microbiome space, including Luca Biologics. Her invaluable contributions to the healthcare industry have earned her recognition as a thought leader and a trusted advisor to CEOs of leading academic centers worldwide, including the Dana Farber Institute and Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute.

With a background as a former lawyer at Wilmer Cutler Pickering Hale and Dorr and expertise in regulatory, policy, and intellectual property matters, Ms. Greenwood brings a unique perspective to the table. Her commitment to advocating for women in science and technology has garnered several awards and honors, including the Science Club for Girls Catalyst Award.

Andrew Hedin, Partner, Bessemer Venture Partners
Andrew Hedin is a partner in Bessemer’s Cambridge office where he focuses on investments broadly across the healthcare ecosystem, including new biotech therapeutics as well as software and services sold to healthcare verticals. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry. He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.

John J. Keilty, Venture Partner, Third Rock Ventures
As a venture partner at Third Rock, John works with the platform team to develop, implement, and refine technology roadmaps for companies across our portfolio with a focus on the identification and integration of drug discovery and development technology platforms.

Prior to joining Third Rock, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he was responsible for information systems, software development, computational science, biostatistics, clinical data management, and clinical informatics. Over the course of almost 13 years at Infinity, John had the unique opportunity to play a critical role in the genesis and evolution of the company's science, technology, and business. John, who has proven to be a sucker for worthy charities, once allowed his coworker to shave his head with a Flowbee to raise money for a local nonprofit organization focused on cancer patient support.

Rana Lonnen, Managing Director, Novartis
Rana Lonnen is a healthcare technology investor, entrepreneur, and molecular biologist. At Novartis, she leads strategic investments in technology companies, on a mission to transform the healthcare ecosystem and make positive impact on people’s lives. Previously, Rana was Head of Preclinical Development at a UK biotech, Auspherix; investment consultant to IP Group in London; Founder and CSO of a UK-based Biotech, Axendos therapeutics. Prior to this, she was a Wellcome Trust-backed principal investigator in drug discovery in the field of Infection, Immunity, and Inflammation, author and inventor on high impact peer-reviewed publications and patents; before this, Rana worked at Bristol-Myers Squibb, in sales and marketing. Rana holds a PhD in molecular biology and an MBA from Imperial College London. She personally cares about equitable healthcare, social justice, sustainability, and the future of antimicrobial resistance. In her downtime, Rana likes to make culinary experiments, be in nature, and read. Rana is a board observer at Aktana, Cota Healthcare, H1 Insights, Koneksa, Mekonos, NuvoAir, and Dopavision. She is based out of Basel, Switzerland.

William T. Mayo, Senior Vice President, Research, IT, Bristol Myers Squibb
A globally oriented technology executive leading research, biotech, and consumer products organizations through complex changes. I have built organizations for explosive growth, consolidated them in business downturns, and led merger/acquisition/divestiture programs. I have led teams in 20+ countries, led all aspects of IT including major business transformations and culture change across organizations. I am an adept strategic thinker with experience advising several early-stage biotech firms, an advisory board member to a software startup, and board chair for large ($100M+) social services agency. I have set technology strategy, implemented global programs, fixed broken operating models, rebuilt teams, negotiated large scale partnerships, and always focused on business success.

Scott T. Megaffin, CEO, Adiso Therapeutics
Proven C-level leader with deep experience running global Fortune 500, start-up, and emerging pharmaceutical businesses, possessing the unique ability to blend, build, and strengthen performance from the ground up. Broad understanding of market strategy development within clinically diverse programs that achieve meaningful product differentiation. Significant accomplishments creating profitable business development and investment community partnerships within the C-suite.

Strategy/Vision:
Deep start-up, transaction and capital raising success through the establishment and guidance of Adiso, Adastra, and Churchill; creation and execution of clinical development and business strategy to lead the companies from formation; with the identification and advancement of multiple first-in-class drug product assets; negotiated and managed lucrative business development partnerships; business development and licensing with Baxalta, transaction to Cothera Bioscience and Sun Pharma FZE.

Change Leadership:
Adaptable and insightful leader instrumental in the cultural and team transformation of Onconova from a private 16-person medicinal chemistry company into a commercially prepared 67-employee Nasdaq listed company executing a successful Initial Public Offering (IPO).

Commercial Innovation:
Directly involved in numerous successful product development/co-development programs and commercial launches within oncology and specialty therapeutics. Demonstrated ability to employ unique approaches to value pricing and contracting within competitive markets.

Execution/Implementation:
Ability to visualize and articulate both long-term and near-term goals while promoting excellence through organization design, leverage of key functional areas, with clear decision making and process application.

Global M&A:
Marshalled Churchill Pharma through nine-month transaction process and successful sale of assets prior to product approval by FDA, while simultaneously preparing for a Churchill launch. While at Onconova, initiated and negotiated two separate license agreements for Japan/Korea and Europe

Mika Newton, CEO, xCures
Mika Newton is an accomplished and visionary leader serving as the CEO of xCures, a prominent healthcare technology company at the forefront of personalized treatment solutions and data-driven insights. With a deep passion for improving patient outcomes and transforming the healthcare landscape, Mika Newton has steered xCures to success through strategic direction, innovative thinking, and a relentless pursuit of excellence. Under Mika Newton's leadership, xCures has secured significant funding, developed its product portfolio, and forged strategic partnerships to revolutionize the delivery of personalized medicine. With a proven track record of driving growth and fostering collaboration, Mika Newton continues to position xCures as a trusted industry leader, harnessing the power of technology and data to empower healthcare providers, enhance patient experiences, and shape the future of healthcare.

Kimberly Nearing, Venture Partner, Investment, BVCF Management Ltd.
Kimberly A. Nearing, M.S., is a Venture Partner at BVCF Management, leading U.S. investing activities including deal origination, execution, fundraising, investor relations, and portfolio management. Additionally, as Chief Business Officer for three biotech companies, she oversees business development, capital raising, and IPO campaigns, and serves as a board member for MaveriX Oncology and the RV Foundation in Washington, D.C. Kimberly has 20 years of international financial services experience in venture capital and investment banking, coupled with substantial life sciences and health tech domain experience in startups and public companies. She began her career at Amgen in BD and marketing, where she served on two product launch teams, and held an executive position at IBM Healthcare where she was elected to a 20-person team charged with developing IBM’s global healthcare strategy. Her career highlight is her global network, particularly in the U.S., Asia, and the Middle East, and cross-border deal-making experience. Her educational background includes an MSc with Honors from Harvard University, a BA in Economics with Distinction from the University of Michigan, and certificates in Healthcare AI/ML from Stanford University and Generative AI: Prompt Engineering from IBM.

Stephanie Oestreich, Managing Director, Myeloma Investment Fund
International marketing and business development professional with proven strategic agility and executional excellence across a broad range of therapy areas and geographies. Strong leadership and change management expertise is combined with 1st class project, alliance management, operational and entrepreneurial experience.

Claire Smith, Partner, SpringTide
Claire is a partner at SpringTide and has spent her career focused at the intersection of healthcare, life sciences, and business. Prior to SpringTide, she was an investor at Meridian Street Capital, where she focused on seed-stage health tech, and Anterra Capital, where she focused on the intersection of biotech and agriculture while launching several animal health startups. Previously, she served as the Chief of Staff at Crestovo, a microbiome therapeutics startup acquired by Finch Therapeutics. She began her career at ClearView Healthcare Partners, a boutique life sciences consultancy, where she advised pharma and biotech clients on a variety of growth strategy topics.

Claire holds bachelor’s degrees in biological engineering and management science from MIT.

She is on the board of Leash Labs and serves as a board observer at IgniteData and Paterna Biosciences

Joanne L. Viney, PhD, Co-Founder & President & CEO, Seismic Therapeutic
Jo is seasoned biotech executive and entrepreneurial scientist who has taken more than a dozen drugs to clinic over her 30-year career.

Prior to founding Seismic, she founded Pandion Therapeutics in 2017 and served as President and Chief Scientific Officer until the acquisition by Merck for $1.85B in 2021. Prior to Pandion, she held research leadership positions at Biogen, Amgen and Immunex. She is an experienced director on both private and public company boards.

In 2024 she was recognized as a Distinguished Fellow by the American Association for Immunologists. In 2022 she was named as one of the Extraordinary Women Advancing Healthcare in Massachusetts by The Women’s Edge, and she was profiled in the Boston Business Journal’s Women to Watch. Jo has also featured in FiercePharma’s 2020 Fiercest Women in Life Sciences and in Endpoints’ 2019 Special Report on 20 Extraordinary Women.

Jo is an advocate for workplace inclusiveness and regularly volunteers her time with organizations focused on increasing diversity. She has served on the board of WEST, a non-profit organization supporting early to mid-career women, including as President 2017-18.

Jo has a PhD in immunology from the University of London, and a BSc (Hons) in biophysics from the University of East London.

Anna Marie Wagner, Independent Board Member & Advisor
Anna Marie Wagner’s career has spanned investing and operating roles in both hypergrowth and mature companies, focused on technology and the life sciences. She currently advises organizations across both the public and private sectors including DARPA and several private techbio innovators. Previously, Anna Marie was on the executive team at Ginkgo Bioworks (NYSE:DNA), where over the years she built and led numerous functions including finance, corporate development, and AI. Anna Marie led Ginkgo’s public offering in 2021, raising $1.6 billion in what still is the largest-ever go-public raise in biotech, and launched Ginkgo's AI efforts, including its marquee collaboration with Google. Previously, she was a technology investor at Bain Capital Private Equity where she focused on vertical software, marketplaces, and digital media businesses. Since 2023, she has also been serving as an Executive Fellow at Harvard Business School, where she co-teaches an elective course on failure (and loves the irony!). Anna Marie lives in Boston and her house is overrun with boys - in the form of a husband, two children, and two cats.